/
OCS
$13.09+$1.09 (+9.08%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$724.7M
60M shares
52-week range
$10.52 – $34.48
11% from low
Exchange
NASDAQ
CS
Borrow rate
5.65%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$2.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $686.0K | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $52.1M | $0 |
| Gross profit | $0 | $0 | $0 | $0 | −$51.4M | $0 |
| Gross margin | — | — | — | — | -7492.3% | — |
| R&D | $9.3M | $9.6M | $22.2M | $29.2M | $52.1M | $54.5M |
| Operating income | −$12.3M | −$13.2M | −$32.4M | −$80.7M | −$73.2M | −$79.1M |
| EBITDA | −$12.1M | −$13.2M | −$31.9M | −$87.1M | −$85.5M | −$93.4M |
| Net income | −$14.9M | −$18.6M | −$38.7M | −$88.8M | −$85.8M | −$94.5M |
| Net margin | — | — | — | — | -12503.9% | — |
| EPS (diluted) | -0.45 | -0.57 | -1.18 | -2.97 | -2.12 | -1.81 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $793325 | $-1.76 | $-2.09–$-1.57 | 8 |
| 2027 | $7M | $-1.71 | $-2.23–$-1.28 | 7 |
| 2028 | $37M | $-1.48 | $-2.44–$-0.04 | 7 |
| 2029 | $109M | $-1.28 | $-4.76–$0.18 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.85
Price
$13.09
Implied downside
-86%
Peer comparison
Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
www.oculis.com- Employees
- 60
- IPO / List date
- Mar 3, 2023
Held by traders on TradeandTell
No one on the platform currently holds OCS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OCS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OCS yet.
